Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.47 |
| ▸ | REN | P00797 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PEPD | P12955 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10658196 | 0.90 | ACE (0.60) | ACERENLMNAKDM4EF2 | |
| SCHEMBL13019815 | 0.90 | ACE (0.60) | ACERENLMNAKDM4EF2 | |
| SCHEMBL19817050 | 0.90 | ACE (0.60) | ACERENLMNAKDM4EF2 | |
| SCHEMBL17323626 | 0.81 | ACE (0.53) | ACERENLMNAKDM4EF2 | |
| SCHEMBL19083734 | 0.81 | ACE (0.53) | ACERENLMNAKDM4EF2 | |
| SCHEMBL30517396 | 0.79 | ACE (0.46) | ACERENLMNAKDM4EF2 | |
| SCHEMBL31618962 | 0.78 | ACE (0.50) | ACERENLMNAKDM4EF2 | |
| SCHEMBL11558715 | 0.78 | ACE (0.50) | ACERENLMNAKDM4EF2 | |
| SCHEMBL30863402 | 0.78 | HRH3 (0.39) | MAPTPEPDHSD17B10RAB9A | |
| SCHEMBL16656669 | 0.76 | PREP (0.47) | ACERENLMNAKDM4EF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197450-A1 | METHOD FOR PRODUCING N-ALKYL AMINO ACID AND PEPTIDE INCLUDING N-ALKYL AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-4414374-A1 | METHOD FOR PRODUCING N-ALKYL AMINO ACID AND PEPTIDE INCLUDING N-ALKYL AMINO ACID | Chugai Seiyaku Kabushiki Kaisha (JP) | 2024-08-14 | — | — | EP | disclosed |
| CN-116507763-A | Peptide synthesis method for inhibiting defects caused by diketopiperazine formation | 中外制药株式会社 | 2023-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197450-A1 | METHOD FOR PRODUCING N-ALKYL AMINO ACID AND PEPTIDE INCLUDING N-ALKYL AMINO ACID | NPPA, MGMT, ANPEP | ACE 1320/4885REN 669/4885LMNA 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.